Autolus Therapeutics plc (AUTL)
NASDAQ: AUTL · Real-Time Price · USD
1.840
-0.315 (-14.62%)
At close: Aug 13, 2025, 4:00 PM
1.940
+0.100 (5.43%)
Pre-market: Aug 14, 2025, 8:57 AM EDT
Autolus Therapeutics Revenue
Autolus Therapeutics had revenue of $20.92M in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to $29.93M, up 185.17% year-over-year. In the year 2024, Autolus Therapeutics had annual revenue of $10.12M with 496.00% growth.
Revenue (ttm)
$29.93M
Revenue Growth
+185.17%
P/S Ratio
16.02
Revenue / Employee
$46,052
Employees
650
Market Cap
489.70M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10.12M | 8.42M | 496.00% |
| Dec 31, 2023 | 1.70M | -4.66M | -73.30% |
| Dec 31, 2022 | 6.36M | 4.03M | 172.96% |
| Dec 31, 2021 | 2.33M | 615.00K | 35.86% |
| Dec 31, 2020 | 1.72M | -1.19M | -41.02% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Sep 30, 2018 | Pro | Pro | Pro |
| Sep 30, 2017 | Pro | Pro | Pro |
| Sep 30, 2016 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
AUTL News
- 1 day ago - Autolus Therapeutics: Expanding The Reach Of Its CD19 Therapy, But Still Far From Profitable - Seeking Alpha
- 1 day ago - Autolus Therapeutics plc (AUTL) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 days ago - Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates - GlobeNewsWire
- 21 days ago - Autolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025 - GlobeNewsWire
- 24 days ago - Autolus Therapeutics' CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) - GlobeNewsWire
- 4 weeks ago - Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress - GlobeNewsWire
- 2 months ago - Autolus: A Buy Before Key Data Readout, Potential Expansion Into Autoimmune Market - Seeking Alpha